Robeco Institutional Asset Management B.V. Sells 125,363 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Robeco Institutional Asset Management B.V. reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 77.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 36,687 shares of the medical equipment provider's stock after selling 125,363 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in Zimmer Biomet were worth $3,960,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Van ECK Associates Corp boosted its position in shares of Zimmer Biomet by 12.4% in the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider's stock worth $391,239,000 after buying an additional 411,163 shares during the period. Janney Montgomery Scott LLC lifted its position in Zimmer Biomet by 181.0% during the 3rd quarter. Janney Montgomery Scott LLC now owns 25,869 shares of the medical equipment provider's stock worth $2,793,000 after acquiring an additional 16,663 shares in the last quarter. Biechele Royce Advisors boosted its holdings in Zimmer Biomet by 21.0% in the 3rd quarter. Biechele Royce Advisors now owns 66,110 shares of the medical equipment provider's stock worth $7,137,000 after acquiring an additional 11,496 shares during the period. Chicago Partners Investment Group LLC raised its stake in shares of Zimmer Biomet by 9.4% during the third quarter. Chicago Partners Investment Group LLC now owns 3,220 shares of the medical equipment provider's stock valued at $337,000 after purchasing an additional 277 shares during the period. Finally, Farther Finance Advisors LLC lifted its position in shares of Zimmer Biomet by 11.2% during the third quarter. Farther Finance Advisors LLC now owns 5,825 shares of the medical equipment provider's stock worth $629,000 after purchasing an additional 587 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Stock Down 0.5 %

Shares of NYSE ZBH traded down $0.51 during midday trading on Friday, hitting $108.18. 1,175,736 shares of the stock traded hands, compared to its average volume of 1,491,025. The company has a market cap of $21.54 billion, a PE ratio of 20.57, a P/E/G ratio of 2.02 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a one year low of $101.47 and a one year high of $133.90. The business has a 50 day moving average price of $106.37 and a two-hundred day moving average price of $110.48.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts' consensus estimates of $1.74. The company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm's quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.65 EPS. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were issued a dividend of $0.24 per share. The ex-dividend date was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. Zimmer Biomet's dividend payout ratio is 18.25%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Royal Bank of Canada lifted their price target on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an "outperform" rating in a research note on Monday, November 4th. Wolfe Research began coverage on Zimmer Biomet in a research report on Tuesday, September 10th. They set a "peer perform" rating on the stock. Morgan Stanley decreased their price target on shares of Zimmer Biomet from $130.00 to $120.00 and set an "equal weight" rating for the company in a research report on Monday, July 15th. TD Cowen cut their target price on shares of Zimmer Biomet from $143.00 to $119.00 and set a "hold" rating on the stock in a research note on Friday, September 6th. Finally, Raymond James decreased their price target on Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating for the company in a research note on Monday, October 14th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $124.11.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.